This site is intended for healthcare professionals
Drug information

Cymevene

POM
Read time: 26 mins
Last updated: 06 May 2020
Published: 01 Apr 2021

4.1 Therapeutic indications

Cymevene is indicated in adults and adolescents ≥ 12 years of age for the:

- treatment of cytomegalovirus (CMV) disease in immunocompromised patients;

- prevention of CMV disease using pre-emptive therapy in patients with drug- induced immunosuppression (for example following organ transplantation or cancer chemotherapy).

Cymevene is also indicated from birth for the:

- prevention of CMV disease using universal prophylaxis in patients with drug- induced immunosuppression (for example following organ transplantation or cancer chemotherapy).

Consideration should be given to official guidance on the appropriate use of antiviral agents.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).